Clinical Edge Journal Scan

Real-world evidence supports use of ribociclib+letrozole in males with HR-positive/HER2-negative BC


 

Key clinical point: Ribociclib plus letrozole was safe and effective in male patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (BC) who did not receive prior endocrine therapy (ET).

Major finding: Male patients vs. overall population experienced fewer treatment-related adverse events (AE), especially neutropenia (all grade 53.8% vs. 74.5%; grade ≥3 41.0% vs. 57.2%). After a median follow-up of 25.4 months, median time to progression was 27.1 months for the overall cohort vs. not reached in males.

Study details: Findings are from an exploratory analysis of the phase 3b CompLEEment-1 trial including 39 males with HR-positive HER2-negative advanced BC who received ribociclib+letrozole but not prior ET for the advanced disease.

Disclosures: The study was supported by Novartis Pharmaceuticals. The authors declared serving as members of speakers’ bureau or receiving honoraria, advisory/consulting fees, expert testimony fees, research grants, or travel and accommodation expenses from several sources, including Novartis. Two authors declared being employees or shareholders of Novartis.

Source: Campone M et al. Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial. Breast Cancer Res Treat. 2022 (Feb 25). Doi: 10.1007/s10549-022-06543-1

Recommended Reading

Heavy drinking in your 20s has lasting impact on cancer risk
Breast Cancer ICYMI
Appropriate cancer screening for women with dense breasts
Breast Cancer ICYMI
FDA approves first PARP inhibitor for early BRCA+ breast cancer
Breast Cancer ICYMI
Doctors treat osteoporosis with hormone therapy against guidelines
Breast Cancer ICYMI
TNBC: Neoadjuvant and adjuvant pembrolizumab prolongs EFS in KEYNOTE-522
Breast Cancer ICYMI
Atezolizumab fails to improve pCR in early TNBC
Breast Cancer ICYMI
Lobular vs. ductal histology worsens outcomes in metastatic breast cancer
Breast Cancer ICYMI
HD201 equivalent to referent trastuzumab in ERBB2-positive early BC
Breast Cancer ICYMI
Metastatic BC: Adding pertuzumab to trastuzumab+chemotherapy prolongs survival in the real world
Breast Cancer ICYMI
Family history of breast cancer increases likelihood of dense breast in premenopausal women
Breast Cancer ICYMI